[Adult refractory Still disease with atypical articular manifestations: efficacity of interleukin-6 antagonists (tocilizumab)].
BACKGROUND
Tocilizumab is a humanized monoclonal antibody directed against interleukin-6 receptor and is beginning to be reported as effective in some cases of Still's disease refractory in adults (ASD). ASD is rare, heterogeneous, with unpredictable evolution. The distal destructive arthritis represents a possible complication.


METHODS
We report an unusual case of adult-onset Still's disease with severe distal interphalangeal destructive arthritis with refractory early and prolonged remission after the first tocilizumab infusion.


CONCLUSIONS
Tocilizumab can be used in patients with refractory ASD after failure or intolerance of conventional treatments.
Service de médecine interne A, hôpital militaire d'instruction Mohammed V, Rabat, Morocco. arkiouak@yahoo.fr
A
A
Rkiouak
K
K
Ennibi
A
A
Zinebi
Y
Y
Akhouad
A
A
Reggad
M
M
Rabhi
J
J
Chaari
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D002358:Cartilage, Articular / Q000000981:diagnostic imaging / Q000473:pathology*; D004351:Drug Resistance; D006225:Hand / Q000000981:diagnostic imaging / Q000473:pathology; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D011859:Radiography; D016706:Still's Disease, Adult-Onset / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D055815:Young Adult; D000093242:Interleukin-6 Inhibitors
D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D008775:Methylprednisolone; D000093242:Interleukin-6 Inhibitors; C502936:tocilizumab